Learning English 1 - Welcome to a meeting

 Good morning. It is an honor to host this meeting.  Over the last fifteen years, the treatment landscape of metastatic renal-cell carcinoma has evolved from a highly toxic and largely ineffective cytokine-based therapy, to a staggering number of highly active agents, that include: oral multikinase inhibitors, anti-angiogenic monoclonal antibodies, mTOR inhibitors and, lately, immunotherapy with both anti-PD1 and anti-CTLA4 agents. What to do in first-line therapy has become frightening due to the realization that not all metastatic kidney cancers are created equal, compounded by the sheer number of available options of single-agent and combination therapies. Over the next two hours we will discuss the fist-line options in mRCC with the help of renowned experts in the field. Through research and academia, each one of them has shaped the field. They are: Dr. Enrique Grande, from the MD Anderson, in Madrid - Spain; Dr. Laurence Albiges, from the Institute Gustave-Roussy, in Paris - France; Dr. Ignacio Duran, from the "Hospital de Valdecillas", in Santander - Spain; and Thomas Powles, who works at Barts Hospital, in London - England. We hope to better inform our treatment decisions for the benefit of our patients. This meeting would not be possible without the support of BMS. We will begin with Dr. Grande's presentation: "The changing landscape of 1L mRCC". Welcome, Dr. Grande...

24.10.2020.